Request for Proposal (RFP) for an Independent Medical Education Grant
AstraZeneca funds independent medical education programs to improve awareness, diagnosis, and treatment knowledge of transthyretin amyloidosis for multidisciplinary healthcare professionals.
Funder: AstraZeneca United States
Due Dates: Rolling (applications reviewed and approved on a rolling basis)
Funding Amounts: Not specified; varies by proposal scope and budget.
Summary: Supports independent medical education programs to raise awareness, improve diagnosis, and disseminate treatment knowledge about transthyretin amyloidosis for healthcare professionals.
Key Information: Emphasis on certified education credits and multidisciplinary reach.
Description
AstraZeneca United States invites proposals for independent medical education (IME/CME) grants focused on transthyretin amyloidosis, including hereditary transthyretin amyloid polyneuropathy (ATTRv-PN) and mixed phenotype (ATTRv-CM with ATTRv-PN). The goal is to expand disease awareness, improve early recognition and diagnosis, and share current and emerging clinical data on ATTRv treatments. Educational initiatives should also address patient care planning and benefit a multidisciplinary audience of healthcare professionals. Programs may utilize diverse learning formats such as live or virtual sessions, enduring materials, podcasts, panel discussions, simulations, patient case studies, and print resources, with a strong emphasis on certified education credits.
